These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32896896)

  • 1. Eleventh meeting of the regional Green Light Committee for the Eastern Mediterranean.
    East Mediterr Health J; 2020 Aug; 26(8):987-988. PubMed ID: 32896896
    [No Abstract]   [Full Text] [Related]  

  • 2. Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
    Gupta R; Raviglione MC; Espinal MA
    Int J Tuberc Lung Dis; 2001 Dec; 5(12):1078-9. PubMed ID: 11769764
    [No Abstract]   [Full Text] [Related]  

  • 3. WHO strategies for the management of drug-resistant tuberculosis.
    Rendon A; Centis R; D'Ambrosio L; Migliori GB
    Arch Bronconeumol; 2017 Mar; 53(3):95-97. PubMed ID: 27717622
    [No Abstract]   [Full Text] [Related]  

  • 4. Control of tuberculosis in India.
    Mohapatra PR
    Lancet; 2003 Oct; 362(9391):1243. PubMed ID: 14568763
    [No Abstract]   [Full Text] [Related]  

  • 5. Analysis of Green Light Committee implementation and acquisition of second-line drug resistance.
    Metcalfe JZ; Vittinghoff E; Hopewell PC
    Clin Infect Dis; 2015 Mar; 60(6):970. PubMed ID: 25527651
    [No Abstract]   [Full Text] [Related]  

  • 6. The most recent report from the World Health Organization found that, worldwide, approximately 5% of new tuberculosis cases are caused by multidrug-resistant strains (MDR TB).
    Denholm J
    J Travel Med; 2010; 17(3):216. PubMed ID: 20536899
    [No Abstract]   [Full Text] [Related]  

  • 7. The tuberculosis emergency in eastern Europe.
    Furin J; Isaakidis P
    Lancet HIV; 2016 Mar; 3(3):e107-8. PubMed ID: 26939731
    [No Abstract]   [Full Text] [Related]  

  • 8. [Multidrug-resistant tuberculosis in Romania].
    Stoicescu IP; Didilescu C; Bercea O
    Pneumoftiziologia; 1997; 46(3):161-78. PubMed ID: 9654954
    [No Abstract]   [Full Text] [Related]  

  • 9. What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?
    Sharma SK; Dheda K
    Indian J Med Res; 2019 Mar; 149(3):309-312. PubMed ID: 31249191
    [No Abstract]   [Full Text] [Related]  

  • 10. New World Health Organization Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared?
    Kranzer K; Kalsdorf B; Heyckendorf J; Andres S; Merker M; Hofmann-Thiel S; Bloemberg GV; Hoffmann H; Niemann S; Lange C; Maurer FP
    Am J Respir Crit Care Med; 2019 Aug; 200(4):514-515. PubMed ID: 31026398
    [No Abstract]   [Full Text] [Related]  

  • 11. Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline.
    Pontali E; D'Ambrosio L; Centis R; Sotgiu G; Migliori GB
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331046
    [No Abstract]   [Full Text] [Related]  

  • 12. Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations.
    Varaine F; Guglielmetti L; Huerga H; Bonnet M; Kiria N; Sitienei JK; Rich M; Mitnick CD
    Am J Respir Crit Care Med; 2016 Oct; 194(8):1028-1029. PubMed ID: 27739887
    [No Abstract]   [Full Text] [Related]  

  • 13. Infectious disease. Drug-resistant TB on the rise.
    Stokstad E
    Science; 2000 Mar; 287(5462):2391. PubMed ID: 10766610
    [No Abstract]   [Full Text] [Related]  

  • 14. Increasing transparency in partnerships for health--introducing the Green Light Committee.
    Gupta R; Cegielski JP; Espinal MA; Henkens M; Kim JY; Lambregts-Van Weezenbeek CS; Lee JW; Raviglione MC; Suarez PG; Varaine F
    Trop Med Int Health; 2002 Nov; 7(11):970-6. PubMed ID: 12390604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mycobacterium tuberculosis with extensive resistance].
    Labie D
    Med Sci (Paris); 2007 Feb; 23(2):205-9. PubMed ID: 17291432
    [No Abstract]   [Full Text] [Related]  

  • 16. Health system factors influencing management of multidrug-resistant tuberculosis in four European Union countries - learning from country experiences.
    de Vries G; Tsolova S; Anderson LF; Gebhard AC; Heldal E; Hollo V; Cejudo LS; Schmid D; Schreuder B; Varleva T; van der Werf MJ
    BMC Public Health; 2017 Apr; 17(1):334. PubMed ID: 28424062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of regimens for drug-resistant tuberculosis.
    Yates TA; Nunn AJ
    Lancet Infect Dis; 2016 Nov; 16(11):1218-1219. PubMed ID: 27788973
    [No Abstract]   [Full Text] [Related]  

  • 18. MDR-TB in Eastern Europe in the era of the TB elimination action framework.
    Dudnyk A; Butov D; Crudu V; Lange C; Chesov D
    Int J Tuberc Lung Dis; 2017 Jan; 21(1):2-3. PubMed ID: 28157456
    [No Abstract]   [Full Text] [Related]  

  • 19. Multidrug-resistant tuberculosis management in resource-limited settings.
    Nathanson E; Lambregts-van Weezenbeek C; Rich ML; Gupta R; Bayona J; Blöndal K; Caminero JA; Cegielski JP; Danilovits M; Espinal MA; Hollo V; Jaramillo E; Leimane V; Mitnick CD; Mukherjee JS; Nunn P; Pasechnikov A; Tupasi T; Wells C; Raviglione MC
    Emerg Infect Dis; 2006 Sep; 12(9):1389-97. PubMed ID: 17073088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Joint Statement on the New WHO Recommendations for Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis].
    Maurer FP; Bauer T; Diel R; Häcker B; Lange C; Niemann S; Otto-Knapp R; Schönfeld N
    Pneumologie; 2019 May; 73(5):270-273. PubMed ID: 31083750
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.